{"id":62127,"date":"2026-04-01T23:29:16","date_gmt":"2026-04-01T15:29:16","guid":{"rendered":"https:\/\/flcube.com\/?p=62127"},"modified":"2026-04-01T23:29:17","modified_gmt":"2026-04-01T15:29:17","slug":"alphamab-oncologys-anbenitamab-meets-primary-endpoint-in-phase-iii-her2-breast-cancer-neoadjuvant-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62127","title":{"rendered":"Alphamab Oncology&#8217;s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study"},"content":{"rendered":"\n<p><strong>Alphamab Oncology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>) announced that the <strong>Phase III KN026-004 clinical study<\/strong> evaluating <strong>anbenitamab<\/strong> in combination with <strong>docetaxel injection (albumin-bound) (HB1801)<\/strong> for <strong>neoadjuvant treatment of HER2-positive breast cancer<\/strong> successfully met its pre-specified primary endpoint, demonstrating <strong>significant improvement in total pathological complete response (tpCR)<\/strong> versus current standard of care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results\">Clinical Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Designation<\/strong><\/td><td>KN026-004 Phase III<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>HER2-positive breast cancer (neoadjuvant setting)<\/td><\/tr><tr><td><strong>Treatment Arm<\/strong><\/td><td>Anbenitamab + albumin-bound docetaxel (HB1801)<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Current standard of care<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Total pathological complete response (tpCR)<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>Statistically significant improvement achieved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-development-status\">Drug Profile &amp; Development Status<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-anbenitamab-characteristics\">Anbenitamab Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Type<\/strong>: Bispecific antibody (BsAb) targeting HER2<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Dual HER2 targeting for enhanced anti-tumor activity<\/li>\n\n\n\n<li><strong>Indications<\/strong>: HER2+ breast cancer and gastric cancer\/gastroesophageal junction cancer<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong>:<\/li>\n\n\n\n<li>NDA under review by NMPA (accepted September 2025)<\/li>\n\n\n\n<li>FDA Orphan Drug Designation for HER2+ or HER2-low gastric cancer<\/li>\n\n\n\n<li>NMPA Breakthrough Therapy Designation for second-line+ HER2+ gastric cancer<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-partnership\">Commercial Partnership<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Licensee<\/strong>: CSPC subsidiary Shanghai JMT Biotechnology<\/li>\n\n\n\n<li><strong>Territory<\/strong>: Mainland China exclusive rights<\/li>\n\n\n\n<li><strong>Indications Covered<\/strong>: Breast and gastric cancers<\/li>\n\n\n\n<li><strong>Deal Year<\/strong>: 2021 licensing agreement<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones-timeline\">Regulatory Milestones Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Agency<\/th><th>Designation<\/th><th>Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>NMPA<\/strong><\/td><td>New Drug Application<\/td><td>HER2+ breast cancer<\/td><td>Under review (accepted Sep 2025)<\/td><\/tr><tr><td><strong>NMPA<\/strong><\/td><td>Breakthrough Therapy<\/td><td>HER2+ gastric\/GEJ cancer (2L+)<\/td><td>Granted<\/td><\/tr><tr><td><strong>FDA<\/strong><\/td><td>Orphan Drug Designation<\/td><td>HER2+ or HER2-low gastric cancer<\/td><td>Granted<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-alphamab-oncology\">For Alphamab Oncology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Validation<\/strong>: Phase III success validates bispecific antibody platform<\/li>\n\n\n\n<li><strong>Commercial Upside<\/strong>: Royalty stream from CSPC partnership upon approval<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Strong clinical data supports potential international expansion<\/li>\n\n\n\n<li><strong>Platform Technology<\/strong>: Demonstrates capability to develop differentiated HER2-targeting biologics<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-cspc-shanghai-jmt\">For CSPC\/Shanghai JMT<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity<\/strong>: First-in-class bispecific antibody for HER2+ breast cancer in China<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Differentiated mechanism versus existing HER2 therapies<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Premium pricing expected for novel bispecific approach<\/li>\n\n\n\n<li><strong>Strategic Asset<\/strong>: Key oncology asset in growing Chinese biologics market<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER2+ Breast Cancer<\/strong>: Represents 15-20% of all breast cancer cases globally<\/li>\n\n\n\n<li><strong>Neoadjuvant Setting<\/strong>: Critical treatment window where tpCR strongly correlates with long-term survival<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Trastuzumab-based regimens dominate but leave room for improvement<\/li>\n\n\n\n<li><strong>Bispecific Innovation<\/strong>: Novel approach combining two HER2 epitopes for enhanced efficacy<\/li>\n\n\n\n<li><strong>Chinese Market<\/strong>: Rapidly growing oncology market with increasing adoption of premium biologics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps-amp-commercial-outlook\">Next Steps &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NDA Review<\/strong>: Expected approval decision from NMPA in 2026<\/li>\n\n\n\n<li><strong>Launch Preparation<\/strong>: CSPC likely preparing commercial infrastructure for rapid market entry<\/li>\n\n\n\n<li><strong>Additional Indications<\/strong>: Potential expansion into adjuvant and metastatic settings<\/li>\n\n\n\n<li><strong>International Strategy<\/strong>: Possible global partnerships following Chinese approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, and commercial potential for anbenitamab. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026033102262_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026033102262_c.\"><\/object><a id=\"wp-block-file--media-5c092c8e-ad38-4872-b68b-0902a378c98c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026033102262_c.pdf\">2026033102262_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026033102262_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5c092c8e-ad38-4872-b68b-0902a378c98c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[187,17,854,28],"class_list":["post-62127","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-alphamab-oncology","tag-clinical-trial-results","tag-hkg-9966","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Oncology&#039;s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in combination with docetaxel injection (albumin-bound) (HB1801) for neoadjuvant treatment of HER2-positive breast cancer successfully met its pre-specified primary endpoint, demonstrating significant improvement in total pathological complete response (tpCR) versus current standard of care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62127\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology&#039;s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in combination with docetaxel injection (albumin-bound) (HB1801) for neoadjuvant treatment of HER2-positive breast cancer successfully met its pre-specified primary endpoint, demonstrating significant improvement in total pathological complete response (tpCR) versus current standard of care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62127\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T15:29:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T15:29:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62127#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62127\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology&#8217;s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study\",\"datePublished\":\"2026-04-01T15:29:16+00:00\",\"dateModified\":\"2026-04-01T15:29:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62127\"},\"wordCount\":453,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alphamab Oncology\",\"Clinical trial results\",\"HKG: 9966\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62127#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62127\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62127\",\"name\":\"Alphamab Oncology's Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-01T15:29:16+00:00\",\"dateModified\":\"2026-04-01T15:29:17+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in combination with docetaxel injection (albumin-bound) (HB1801) for neoadjuvant treatment of HER2-positive breast cancer successfully met its pre-specified primary endpoint, demonstrating significant improvement in total pathological complete response (tpCR) versus current standard of care.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62127#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62127\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62127#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology&#8217;s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology's Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in combination with docetaxel injection (albumin-bound) (HB1801) for neoadjuvant treatment of HER2-positive breast cancer successfully met its pre-specified primary endpoint, demonstrating significant improvement in total pathological complete response (tpCR) versus current standard of care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62127","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology's Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study","og_description":"Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in combination with docetaxel injection (albumin-bound) (HB1801) for neoadjuvant treatment of HER2-positive breast cancer successfully met its pre-specified primary endpoint, demonstrating significant improvement in total pathological complete response (tpCR) versus current standard of care.","og_url":"https:\/\/flcube.com\/?p=62127","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T15:29:16+00:00","article_modified_time":"2026-04-01T15:29:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62127#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62127"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology&#8217;s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study","datePublished":"2026-04-01T15:29:16+00:00","dateModified":"2026-04-01T15:29:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62127"},"wordCount":453,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alphamab Oncology","Clinical trial results","HKG: 9966","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62127#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62127","url":"https:\/\/flcube.com\/?p=62127","name":"Alphamab Oncology's Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-01T15:29:16+00:00","dateModified":"2026-04-01T15:29:17+00:00","description":"Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in combination with docetaxel injection (albumin-bound) (HB1801) for neoadjuvant treatment of HER2-positive breast cancer successfully met its pre-specified primary endpoint, demonstrating significant improvement in total pathological complete response (tpCR) versus current standard of care.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62127#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62127"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62127#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology&#8217;s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62127"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62127\/revisions"}],"predecessor-version":[{"id":62130,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62127\/revisions\/62130"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}